Connect your AI

Crinetics Pharmaceuticals CRNX Restricted Cash

Restricted Cash at other companies

Mineralys Therapeutics, Inc.MLYS

$0—

Amneal Pharmaceuticals, Inc.AMRX

$4.17M-36.6%

Rhythm Pharmaceuticals, Inc.RYTM

$601K+29.5%

LQD

Liquidia CorporationLQDA

$3.5M—

Neurocrine BiosciencesNBIX

——

Corcept TherapeuticsCORT

——

Other financials

Income statement

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

Market cap$3.79B+21.9%

Profitability

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCash.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Crinetics Pharmaceuticals's restricted cash?: Crinetics Pharmaceuticals (CRNX) reported restricted cash of $800K in Q1 2026.
How has Crinetics Pharmaceuticals's restricted cash changed year-over-year?: Crinetics Pharmaceuticals's restricted cash increased by 60.0% year-over-year, from $500K to $800K.
What is the long-term trend for Crinetics Pharmaceuticals's restricted cash?: Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $500K to $0.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.